Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Deals report: BridgeBio taps Bayer as EU partner

Plus: Viatris deal extends Idorsia’s runway; AbbVie-OSE; Merck KGaA-C4

By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
March 5, 2024 1:32 AM UTC

With amyloidosis therapy acoramidis now under regulatory review in both the U.S. and EU, BridgeBio has chosen Bayer as its local partner ahead of a planned 2025 launch in Europe.

BridgeBio Pharma Inc. (NASDAQ:BBIO) is to receive $310 million in upfront and near-term payments, as well as undisclosed sales milestones and tiered royalties beginning “in the low thirties percent,” the company said. Bayer AG (Xetra:BAYN) will receive an exclusive license to the product in Europe...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Abbvie Inc.

Bayer AG

Bridgebio Pharma Inc.

C4 Therapeutics Inc.

Idorsia Ltd.

Merck KGaA

Ose Immunotherapeutics S.A.